Pancragen Alternatives

A synthetic small molecule developed at Saint Louis University that activates estrogen-related receptors (ERRs), mimicking the metabolic effects of aerobic exercise. Technically not a peptide but a small organic molecule (MW 290.32), widely discussed in the peptide community as an "exercise mimetic" that boosts fat oxidation, endurance, and mitochondrial function without stimulant effects.

An orally administered cyclized small peptide that mimics bone morphogenetic protein 7 (BMP-7) signaling through the ALK3 receptor. Originally developed for kidney fibrosis where it reversed established fibrosis in animal models. A 2025 Nature Communications study from the Diabetes Research Institute showed THR-123 regenerated insulin-producing pancreatic beta cells and reversed diabetes in preclinical models. No human clinical trials yet.

A synthetic peptide derived from a protein found in human gastric juice. Known for its remarkable tissue healing properties across multiple body systems. FDA classified as Category 2 in 2023, restricting compounding.

A synthetic 17-amino acid fragment of Thymosin Beta-4 (TB-4). Unlike TB-4, TB-500 has a longer half-life (~2-4 days vs ~2 hours) and is the active region responsible for tissue repair and cell migration. Note: Many vendors mislabel TB-4 as 'TB-500' in premixed products.

A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.